- Home
- IPW vs LSTA Comparison
IPW vs LSTA Comparison
Compare IPW & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- LSTA
- Stock Information
- Founded
- IPW 2018
- LSTA 1980
- Country
- IPW United States
- LSTA United States
- Employees
- IPW N/A
- LSTA N/A
- Industry
- IPW Catalog/Specialty Distribution
- LSTA Misc Health and Biotechnology Services
- Sector
- IPW Consumer Discretionary
- LSTA Health Care
- Exchange
- IPW Nasdaq
- LSTA Nasdaq
- Market Cap
- IPW 19.8M
- LSTA 22.3M
- IPO Year
- IPW 2021
- LSTA N/A
- Fundamental
- Price
- IPW $0.59
- LSTA $2.15
- Analyst Decision
- IPW
- LSTA Strong Buy
- Analyst Count
- IPW 0
- LSTA 2
- Target Price
- IPW N/A
- LSTA $23.50
- AVG Volume (30 Days)
- IPW 139.3K
- LSTA 21.9K
- Earning Date
- IPW 11-13-2025
- LSTA 11-11-2025
- Dividend Yield
- IPW N/A
- LSTA N/A
- EPS Growth
- IPW N/A
- LSTA N/A
- EPS
- IPW N/A
- LSTA N/A
- Revenue
- IPW $74,105,251.00
- LSTA $1,070,000.00
- Revenue This Year
- IPW $8.31
- LSTA N/A
- Revenue Next Year
- IPW $77.15
- LSTA N/A
- P/E Ratio
- IPW N/A
- LSTA N/A
- Revenue Growth
- IPW N/A
- LSTA N/A
- 52 Week Low
- IPW $0.41
- LSTA $1.87
- 52 Week High
- IPW $2.36
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- IPW 55.48
- LSTA 38.47
- Support Level
- IPW $0.49
- LSTA $2.11
- Resistance Level
- IPW $0.55
- LSTA $2.33
- Average True Range (ATR)
- IPW 0.05
- LSTA 0.16
- MACD
- IPW 0.01
- LSTA -0.01
- Stochastic Oscillator
- IPW 73.53
- LSTA 14.81
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.